Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 41 entries
View as:

Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04497948 Org: User:
Start: 09/21/20 End: 11/18/20 Due: 11/18/21

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02112526 Org: User:
Start: 08/07/14 End: 10/04/24 Due: 10/04/25

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Phase: N/A Priority: Normal
NCT ID: NCT02972840 Org: User:
Start: 04/05/17 End: 10/28/25 Due: 10/28/26

A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196

Phase: N/A Priority: Normal
NCT ID: NCT04867941 Org: User:
Start: 10/21/14 End: 02/02/15 Due: 02/02/16

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Phase: N/A Priority: Normal
NCT ID: NCT02970318 Org: User:
Start: 02/02/17 End: 10/01/27 Due: 10/01/28

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05140096 Org: User:
Start: 01/03/20 End: 04/15/20 Due: 04/15/21

Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Phase: N/A Priority: Normal
NCT ID: NCT02475681 Org: User:
Start: 06/26/15 End: 09/30/25 Due: 09/30/26

A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04898101 Org: User:
Start: 03/03/16 End: 04/13/16 Due: 04/13/17

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Phase: N/A Priority: Normal
NCT ID: NCT02717624 Org: User:
Start: 04/20/16 End: 08/20/27 Due: 08/20/28

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Phase: N/A Priority: Normal
NCT ID: NCT03968848 Org: User:
Start: 11/12/18 End: 03/29/19 Due: 03/29/20

Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL

Phase: N/A Priority: Normal
NCT ID: NCT02296918 Org: User:
Start: 12/22/14 End: 09/06/27 Due: 09/06/28

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT03328273 Org: User:
Start: 01/31/18 End: 08/26/26 Due: 08/26/27

ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02362048 Org: User:
Start: 05/31/15 End: 03/31/17 Due: 03/31/18

Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02351739 Org: User:
Start: 04/30/15 End: 04/30/18 Due: 04/30/19

Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02448303 Org: User:
Start: 05/31/15 End: 06/30/18 Due: 06/30/19

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02328014 Org: User:
Start: 12/20/14 End: 04/01/26 Due: 04/01/27

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02362035 Org: User:
Start: 02/20/15 End: 04/01/26 Due: 04/01/27

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

Phase: N/A Priority: Normal
NCT ID: NCT02586857 Org: User:
Start: 01/25/16 End: 04/01/26 Due: 04/01/27

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02735876 Org: User:
Start: 05/31/16 End: - Due: -

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04901923 Org: User:
Start: 03/15/14 End: 05/22/14 Due: 05/22/15

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Phase: N/A Priority: Normal
NCT ID: NCT02337829 Org: User:
Start: 01/12/15 End: 04/01/26 Due: 04/01/27

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02213926 Org: User:
Start: 03/02/15 End: 09/06/26 Due: 09/06/27

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02157324 Org: User:
Start: 08/18/14 End: 04/01/26 Due: 04/01/27

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT03205046 Org: User:
Start: 06/29/17 End: 11/20/19 Due: 11/20/20

Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02454179 Org: User:
Start: 05/31/15 End: 07/31/18 Due: 07/31/19